Almac opens cold storage facility at Northern Ireland HQ

almac
CDMO Almac has opened a $27.6 million cold storage facility at its Northern Ireland headquarters with space for more than 3,000 pallets. (Almac Group)

CDMO Almac, which has been bulking up its capacity and services, has opened a new cold storage facility at its Northern Ireland headquarters campus.

The company said that it has completed a £20 million ($27.6 million), 95,000-square-foot warehouse for both clinical supplies and drug products. The facility has space for more than 3,000 pallets, including -15°C to -25°C storage capacity, additional 2°C – 8°C secondary production rooms, 3PL processing areas and a custom designed clinical labeling suite.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The company claims it is among the largest in Europe and will help meet changing regulatory requirements and a growing demand for space that can handle orphan and other specialty drugs.

"This new facility at our global headquarters expands our cold storage capacity by 300% and our frozen storage capabilities by over 50%," Almac CEO Alan Armstrong said in a statement.

RELATED: CDMO Almac continues its expansion momentum with lab deal 

Almac has been expanding and last fall acquired BioClin Laboratories, a drug testing and analytical services company that is based in Athlone, Ireland, just two hours away from Almac Group’s headquarters in Craigavon.

Almac said that BioClin’s expertise and 14,000-square-foot facility significantly increases its analytical capacity and capabilities.  It has already invested $6.3 million (£5 million) to build an additional laboratory and office facility at its headquarters.

Suggested Articles

Spectrum Pharmaceuticals has pulled its biologics license application for Rolontis because the FDA needs more CMC information.

Samsung BioLogics has faced scrutiny of a biosimilars joint venture. Now, officials are looking more closely into the company's 2016 public listing.

Lupin has indicated it has received another FDA warning letter as regulatory issues continue to pile up for the Indian drugmaker.